Alignment Healthcare (ALHC) CEO’s trust sells 118K shares under Rule 10b5-1 plan

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Alignment Healthcare, Inc. director and Chief Executive Officer John E. Kao reported an open-market sale of 118,000 shares of Common Stock at a weighted-average price of $17.4783 per share. The sale was effected indirectly through JEK Trust, dated February 8, 2021, for which he serves as trustee, under a Rule 10b5-1 trading plan adopted on November 21, 2025. Following the transaction, indirect holdings through the trust were 2,354,641 shares, and a separate holding entry shows 1,784,868 shares held directly.

Insights

CEO’s trust sells a small portion of total holdings under a pre-set plan.

Chief Executive Officer John E. Kao, via the JEK Trust, sold 118,000 Alignment Healthcare shares at a weighted-average price of $17.4783. The sale occurred under a Rule 10b5-1 trading plan adopted on November 21, 2025, indicating it was pre-arranged.

After the sale, the trust still held 2,354,641 shares indirectly, and a separate entry shows 1,784,868 shares held directly. Relative to these combined holdings, the sale size appears modest, suggesting routine portfolio management rather than a major change in the CEO’s overall equity exposure.

Insider Trade Summary 10b5-1

Net Seller: 118,000 shares ($2,062,439)

Net Sell 2 txns

Insider KAO JOHN E

Role Chief Executive Officer

Sold 118,000 shs ($2.06M)

Type	Security	Shares	Price	Value
Sale	Common Stock	118,000	$17.4783	$2.06M
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 2,354,641 shares (Indirect, See Footnote); Common Stock — 1,784,868 shares (Direct)

Footnotes (1)

Date of Rule 10b5-1 plan adoption: 11/21/25 The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $17.07 to $17.81. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range. Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

03/23/2026 - 05:36 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KAO JOHN E

(Last)

(First)

(Middle)

1100 W. TOWN & COUNTRY RD., SUITE 1600

(Street)

ORANGE

CALIFORNIA

92868

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Alignment Healthcare, Inc. [ ALHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/23/2026		S⁽¹⁾		118,000	D	$17.4783⁽²⁾	2,354,641	I	See Footnote⁽³⁾
Common Stock								1,784,868	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Date of Rule 10b5-1 plan adoption: 11/21/25

2. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $17.07 to $17.81. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

3. Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

Remarks:

	/s/ Christopher J. Joyce, as Attorney-in-Fact, for John E. Kao	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Alignment Healthcare (ALHC) disclose for John E. Kao?

Alignment Healthcare disclosed that CEO and director John E. Kao, through the JEK Trust, sold 118,000 shares of Common Stock. The weighted-average sale price was $17.4783 per share across multiple trades within a specified price range.

At what prices did John E. Kao’s trust sell Alignment Healthcare (ALHC) shares?

The trust’s reported weighted-average sale price was $17.4783 per share. Individual trades occurred at prices ranging from $17.07 to $17.81 per share, with the issuer noting that detailed trade-by-trade information is available upon request.

Was the Alignment Healthcare (ALHC) insider sale by John E. Kao pre-planned?

Yes. The filing notes the sale was executed under a Rule 10b5-1 trading plan adopted on November 21, 2025. Such plans pre-schedule trades, reducing the significance of short-term market timing for interpreting insider intent.

How many Alignment Healthcare (ALHC) shares does John E. Kao hold after the reported sale?

After the transaction, indirect holdings through the JEK Trust totaled 2,354,641 shares. A separate holding entry shows 1,784,868 shares held directly, indicating a substantial remaining ownership position in Alignment Healthcare following the disclosed sale.

Who actually held the Alignment Healthcare (ALHC) shares sold in this Form 4 filing?

The shares were held by the JEK Trust, dated February 8, 2021, for which John E. Kao serves as trustee. The transaction is therefore attributed to this trust, an entity associated with Kao, rather than to a personal account.

What does the price range in John E. Kao’s Alignment Healthcare (ALHC) sale indicate?

The filing states the reported price is a weighted average, with individual trades between $17.07 and $17.81 per share. This shows the 118,000 shares were sold in multiple market transactions rather than in a single block at one price.